ArticleResearch square2025
Single-day accelerated TMS with D-cycloserine augmentation for depression: A placebo-controlled trial.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07593222 (Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accelerated transcranial magnetic stimulation (TMS) protocols have the potential to rapidly treat depression, yet the synaptic mechanisms underlying these intensive interventions remain poorly understood. d-cycloserine (DCS), a partial NMDAR agonist, enhances TMS-induced corticomotor plasticity and conventional daily TMS outcomes, but its effects on accelerated protocols are unknown. We conducted a double-blind placebo-controlled trial examining whether DCS could enhance single-day accelerated intermittent theta-burst stimulation (iTBS) in 30 participants with major depressive disorder. Participants received either 250 mg DCS or placebo the night before undergoing 10 iTBS treatments (1 800 pulses/treatment) delivered hourly to the left dorsolateral prefrontal cortex. Motor-evoked potentials (MEPs) were recorded before and after each treatment to assess corticomotor excitability, while depression severity was measured at baseline and one-week post-treatment using PHQ-9 and QIDS-SR16 scales. Normalized MEP amplitudes were analyzed using separate generalized linear mixed models for pre- and post-iTBS measurements, revealing a significant Group × Treatment interaction in only the pre-iTBS data (χ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.